265 related articles for article (PubMed ID: 37390896)
1. High-throughput proteomics of breast cancer subtypes: Biological characterization and multiple candidate biomarker panels to patients' stratification.
Azevedo ALK; Gomig THB; Batista M; Marchini FK; Spautz CC; Rabinovich I; Sebastião APM; Oliveira JC; Gradia DF; Cavalli IJ; Ribeiro EMSF
J Proteomics; 2023 Aug; 285():104955. PubMed ID: 37390896
[TBL] [Abstract][Full Text] [Related]
2. Multipronged quantitative proteomics reveals serum proteome alterations in breast cancer intrinsic subtypes.
Gajbhiye A; Dabhi R; Taunk K; Jagadeeshaprasad MG; RoyChoudhury S; Mane A; Bayatigeri S; Chaudhury K; Santra MK; Rapole S
J Proteomics; 2017 Jun; 163():1-13. PubMed ID: 28495502
[TBL] [Abstract][Full Text] [Related]
3. High-throughput proteomics of breast cancer interstitial fluid: identification of tumor subtype-specific serologically relevant biomarkers.
Terkelsen T; Pernemalm M; Gromov P; Børresen-Dale AL; Krogh A; Haakensen VD; Lethiö J; Papaleo E; Gromova I
Mol Oncol; 2021 Feb; 15(2):429-461. PubMed ID: 33176066
[TBL] [Abstract][Full Text] [Related]
4. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.
Bastien RR; Rodríguez-Lescure Á; Ebbert MT; Prat A; Munárriz B; Rowe L; Miller P; Ruiz-Borrego M; Anderson D; Lyons B; Álvarez I; Dowell T; Wall D; Seguí MÁ; Barley L; Boucher KM; Alba E; Pappas L; Davis CA; Aranda I; Fauron C; Stijleman IJ; Palacios J; Antón A; Carrasco E; Caballero R; Ellis MJ; Nielsen TO; Perou CM; Astill M; Bernard PS; Martín M
BMC Med Genomics; 2012 Oct; 5():44. PubMed ID: 23035882
[TBL] [Abstract][Full Text] [Related]
5. Quantitative proteomic analysis of HER2 normal and overexpressing MCF-7 breast cancer cells revealed proteomic changes accompanied with HER2 gene amplification.
Tang Y; Mackey J; Lai R; Ghosh S; Santos C; Graham K; Damaraju S; Pasdar M; Li L
J Proteomics; 2013 Oct; 91():200-9. PubMed ID: 23851309
[TBL] [Abstract][Full Text] [Related]
6. Using feature selection and Bayesian network identify cancer subtypes based on proteomic data.
Wang Y; Gao X; Ru X; Sun P; Wang J
J Proteomics; 2023 May; 280():104895. PubMed ID: 37024076
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer classification by proteomic technologies: current state of knowledge.
Lam SW; Jimenez CR; Boven E
Cancer Treat Rev; 2014 Feb; 40(1):129-38. PubMed ID: 23891266
[TBL] [Abstract][Full Text] [Related]
8. Characterization of Hormone Receptor and HER2 Status in Breast Cancer Using Mass Spectrometry Imaging.
Gonçalves JPL; Bollwein C; Noske A; Jacob A; Jank P; Loibl S; Nekljudova V; Fasching PA; Karn T; Marmé F; Müller V; Schem C; Sinn BV; Stickeler E; van Mackelenbergh M; Schmitt WD; Denkert C; Weichert W; Schwamborn K
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769215
[TBL] [Abstract][Full Text] [Related]
9. Quantitative tissue proteomic investigation of invasive ductal carcinoma of breast with luminal B HER2 positive and HER2 enriched subtypes towards potential diagnostic and therapeutic biomarkers.
Pendharkar N; Gajbhiye A; Taunk K; RoyChoudhury S; Dhali S; Seal S; Mane A; Abhang S; Santra MK; Chaudhury K; Rapole S
J Proteomics; 2016 Jan; 132():112-30. PubMed ID: 26642762
[TBL] [Abstract][Full Text] [Related]
10. Subtype classification for prediction of prognosis of breast cancer from a biomarker panel: correlations and indications.
Chen C; Yuan JP; Wei W; Tu Y; Yao F; Yang XQ; Sun JZ; Sun SR; Li Y
Int J Nanomedicine; 2014; 9():1039-48. PubMed ID: 24591826
[TBL] [Abstract][Full Text] [Related]
11. Urinary proteome alterations in HER2 enriched breast cancer revealed by multipronged quantitative proteomics.
Gajbhiye A; Dabhi R; Taunk K; Vannuruswamy G; RoyChoudhury S; Adhav R; Seal S; Mane A; Bayatigeri S; Santra MK; Chaudhury K; Rapole S
Proteomics; 2016 Sep; 16(17):2403-18. PubMed ID: 27324523
[TBL] [Abstract][Full Text] [Related]
12. Characterizing the Relapse Potential in Different Luminal Subtypes of Breast Cancers with Functional Proteomics.
Lin TY; Wang PW; Huang CH; Yang PM; Pan TL
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32846884
[TBL] [Abstract][Full Text] [Related]
13. Breast Cancer Classification Based on Proteotypes Obtained by SWATH Mass Spectrometry.
Bouchal P; Schubert OT; Faktor J; Capkova L; Imrichova H; Zoufalova K; Paralova V; Hrstka R; Liu Y; Ebhardt HA; Budinska E; Nenutil R; Aebersold R
Cell Rep; 2019 Jul; 28(3):832-843.e7. PubMed ID: 31315058
[TBL] [Abstract][Full Text] [Related]
14. Novel secretome-to-transcriptome integrated or secreto-transcriptomic approach to reveal liquid biopsy biomarkers for predicting individualized prognosis of breast cancer patients.
Ankney JA; Xie L; Wrobel JA; Wang L; Chen X
BMC Med Genomics; 2019 May; 12(1):78. PubMed ID: 31146747
[TBL] [Abstract][Full Text] [Related]
15. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
[TBL] [Abstract][Full Text] [Related]
17. Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer.
Cabezón T; Gromova I; Gromov P; Serizawa R; Timmermans Wielenga V; Kroman N; Celis JE; Moreira JM
Mol Cell Proteomics; 2013 Feb; 12(2):381-94. PubMed ID: 23172894
[TBL] [Abstract][Full Text] [Related]
18. Protein biomarkers for subtyping breast cancer and implications for future research.
Mueller C; Haymond A; Davis JB; Williams A; Espina V
Expert Rev Proteomics; 2018 Feb; 15(2):131-152. PubMed ID: 29271260
[TBL] [Abstract][Full Text] [Related]
19. Combined analysis of receptor expression reflects inter-and intra-tumor heterogeneity in HR+/HER2+ breast cancer.
Ju J; Du F; Gao SL; Si YR; Hu NL; Liu DX; Wang X; Yue J; Zheng FC; Kang YK; Yang ZX; Ma F; Xu BH; Yuan P
Breast Cancer Res Treat; 2022 Jul; 194(2):221-230. PubMed ID: 35699854
[TBL] [Abstract][Full Text] [Related]
20. Survival analysis in breast cancer using proteomic data from four independent datasets.
Ősz Á; Lánczky A; Győrffy B
Sci Rep; 2021 Aug; 11(1):16787. PubMed ID: 34408238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
